12:00 AM
 | 
May 11, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Bronchitol mannitol: Phase III data

Data from the double-blind, international Phase III DPM- CF-301 trial in 324 CF patients showed that Bronchitol met the primary endpoint of significantly improving lung function as measured by FEV1 from baseline vs. placebo at week 26 (p=0.001). Bronchitol also met a secondary endpoint of significantly improving FEV1 from baseline vs. placebo in patients concurrently receiving...

Read the full 264 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >